TABLE 2.
Clinical studies using radiolabeled SSTR2 ligands for meningioma diagnosis.
| Image diagnostic method | Radiolabeled SSTR2 ligand | Sample size | Major/novel functions | References |
| PET | 68Ga-DOTATATE | 21 pts (81 Ms) | Discriminating meningioma and tumor-free tissue even in recurrent tumors after previous therapy. | (46) |
| 64 Ms | Selecting the time point for treatment initiation; predicting tumor growth rate | (48) | ||
| 30 pts (49 Ms) | Discriminating meningioma and post-treatment change; improving diagnosis and extent of disease evaluation. | (50) | ||
| 68Ga-DOTATOC | 3 pts (8 Ms) | Offering excellent imaging properties and a very high tumor-to-background ratio even in small meningiomas. | (49) | |
| 21 pts | Showing higher specificity for meningioma diagnosis than FET PET. | (54) | ||
| PET/CT | 68Ga-DOTATATE | 82 pts | Improving detection of the transosseous extension of intracranial meningiomas. | (53) |
| 68Ga-DOTATOC | 26 pts | Improving target volume delineation for IMRT especially for skull base meningioma and recurrent disease after surgery | (47) | |
| 134 pts | Providing additional information in patients with uncertain or equivocal results on MRI; helping to confirm MRI-based diagnosis of meningiomas in cases of biopsy limitations. | (52) | ||
| PET/MRI | 68Ga-DOTATOC | 10 pts | Sketching treatment target volume; benefiting radiosurgical treatment planning. | (51) |
| SPECT SRS | 111In-octreotide | 27 pts | Discriminating meningioma and nonspecific hyperperfusion; displaying remaining tumor tissue or relapse of meningioma in postsurgical follow-up. | (60) |
| 22 pts | Detecting Ms with an extremely high sensitivity (100%). | (62) | ||
| 47 pts | Discriminating Ms and other CNS tumors, combined with MRI. | (63) | ||
| 70 pts | Discriminating Ms and other tumors, postoperative scar or radionecrosis at the skull base. | (64) | ||
| 95 pts | Discriminating Ms and other CNS tumors. | (65) | ||
| 50 pts | Discriminating Ms and other cranial dural-based lesions, combined with MRI. | (66) | ||
| SPECT/CT SRS | 99mTc-HYNIC-octreotide | 30 pts | Showing high meningioma radioactivity accumulation with a sensitivity of 100 %. | (70) |
CNS, central nervous system; DOTATATE, DOTA-D-Phe1-Tyr3-octreotate; DOTATOC, DOTA-(Tyr3)-octreotide; FET, fluoro-ethyl-tyrosine; IMRT, intensity modulated radiotherapy; 111In, 111-Indium; MRI, Magnetic Resonance Imaging; Ms, meningiomas; PET, Positron emission tomography; pts, patients; SPECT, single-photon emission computed tomography; and SRS, Somatostatin receptor scintigraphy.